The Food and Drug Administration still hasn’t announced whether it will authorize Pfizer–BioNTech Covid booster shots for some Americans even as a key Centers for Disease Control and Prevention vaccine advisory group concludes its first day of a two-day meeting on the topic.

Normally, the FDA will announce its decision on vaccines before the CDC or its Advisory Committee on Immunization Practices meet to make their recommendations. Officials said that the CDC panel was supposed to vote Thursday on booster shots, but they would postpone the meeting if it wasn’t made public by the FDA before the committee meets at noon.

Friday’s FDA Vaccines and Related Biological Products Advisory Committee overwhelmingly rejected a plan to provide booster shots for Americans older than 16 years. However, they unanimously endorsed a new plan that will give boosts to those who are at higher risk or have severe illnesses.

It was considered a controversial recommendation because the Biden administration has said it wants to begin offering booster shots to the general public as early as this week, pending authorization from U.S. health regulators.

It’s now up to FDA regulators to decide whether they will accept that agency’s advisory committee’s recommendation – which it often does – or perhaps depart from the advice given and increase the number of people who are eligible to get the extra shots.

A spokesperson for the FDA declined to comment on the time frame of the agency’s decision.

Still, the FDA has time. While the CDC advisory committee isn’t likely to vote on Pfizer’s booster shots before Thursday afternoon, federal officials suggested Wednesday that they could push the vote back to another day if FDA does not make its decision.

During the Wednesday meeting, CDC advisers listened closely to several presentations of data supporting wide distributions of booster shots. The presentation by a Pfizer executive showed data that suggested that a third shot was safe for recipients and could boost their antibody levels.